ライフサイエンスコーパス: trypanosomiasis

1 surgence in sleeping sickness (human African trypanosomiasis).

2 yma is a major pathogenetic event in African trypanosomiasis.

3 diseases such as malaria, toxoplasmosis, and trypanosomiasis.

4 and new developments in vaccination against trypanosomiasis.

5 nfections such as tuberculosis, malaria, and trypanosomiasis.

6 omising therapeutic target for human African trypanosomiasis.

7 tential novel drug targets for human African trypanosomiasis.

8 PTR1 may be a drug target for human African trypanosomiasis.

9 ment of new treatments against human African trypanosomiasis.

10 t and prevention of human and animal African trypanosomiasis.

11 ly reproducible mouse model of human African trypanosomiasis.

12 get for new compounds to treat human African trypanosomiasis.

13 infected animals in the acute mouse model of trypanosomiasis.

14 animals in the STIB900 acute mouse model of trypanosomiasis.

15 animals in the acute mouse model of African trypanosomiasis.

16 ion could have therapeutic potential against trypanosomiasis.

17 is definitively linked to host resistance in trypanosomiasis.

18 variant cross-specific immunity for African trypanosomiasis.

19 tory and regulatory mediators during African trypanosomiasis.

20 ng phase III clinical trials against African trypanosomiasis.

21 ibitors of therapeutic value against African trypanosomiasis.

22 mportant chemotherapeutic target for African trypanosomiasis.

23 ises the use of antifolates for treatment of trypanosomiasis.

24 imulation of the host immune response during trypanosomiasis.

25 to control tsetse flies and, hence, African trypanosomiasis.

26 mals in the STIB900 animal model for African trypanosomiasis.

27 developed for the treatment of human African trypanosomiasis.

28 es (PMCAs) of T. brucei, an agent of African trypanosomiasis.

29 r developing new serodiagnostics for African trypanosomiasis.

30 robial peptides for the treatment of African trypanosomiasis.

31 omes overcome host resistance during African trypanosomiasis.

32 fforts to develop effective vaccines against trypanosomiasis.

33 some in vivo activity in a model of African trypanosomiasis.

34 nisms of tropical diseases leishmaniasis and trypanosomiasis.

35 ic Th-cell responses in experimental African trypanosomiasis.

36 d compound for treatment of cancer, HIV, and trypanosomiasis.

37 pment of specific drugs and vaccines against trypanosomiasis.

38 chemotherapeutic target for the treatment of trypanosomiasis.

39 the parasites that cause malaria and African trypanosomiasis.

40 or T.b. gambiense, which cause human African trypanosomiasis.

41 inidae), vectors of Human and Animal African trypanosomiasis.

42 ackbone of the pharmacopoeia against African trypanosomiasis.

43 compounds for the treatment of human African trypanosomiasis.

44 peutic target for treatment of human African trypanosomiasis.

45 in the STIB900 mouse model for human African trypanosomiasis.

46 e blood meal of tsetse flies, the vector for trypanosomiasis.

47 ns as potential therapeutic drug targets for trypanosomiasis.

48 ucei is the causative agent of human African trypanosomiasis.

49 development of drugs to treat human African trypanosomiasis.

50 t of a combination therapy for human African trypanosomiasis.

51 oan responsible for human and animal African trypanosomiasis.

52 osoma brucei, the causative agent of African trypanosomiasis.

53 ead for development of drugs against African trypanosomiasis.

54 al target for the treatment of human African trypanosomiasis.

55 brucei, the causative agent of human African trypanosomiasis.

56 brucei, the causative agent of human African trypanosomiasis.

57 ed, with a particular focus on human African trypanosomiasis.

58 ed target for the treatment of human African trypanosomiasis.

59 osoma brucei is the causing agent of African trypanosomiasis.

60 Animal African trypanosomiasis (AAT), caused by Trypanosoma congolense

61 the efficacy of treatment for human African trypanosomiasis, accurate tests that can discriminate re

62 brucei, the causative agent of human African trypanosomiasis, affects tens of thousands of sub-Sahara

63 Human African trypanosomiasis, also known as sleeping sickness, affect

64 Human African trypanosomiasis, also known as sleeping sickness, is a n

65 c signatures characteristic of human African trypanosomiasis among 206 protein clusters.

66 serum samples from 85 patients with African trypanosomiasis and 146 control patients who had other p

67 ed to the taxa responsible for human African trypanosomiasis and Chagas disease.

68 Trypanosoma brucei causes African trypanosomiasis and contains three full-length oligosacc

69 to diseases such as malaria, leishmaniasis, trypanosomiasis and dysentery that are responsible for m

70 s TbCLK1 as a therapeutic target for African trypanosomiasis and establishes a new chemoproteomic too

71 rypanosoma brucei causes fatal human African trypanosomiasis and evades the host immune response by r

72 in the trypanosomatid parasites, which cause trypanosomiasis and leishmaniasis.

73 l as therapeutic agents for the treatment of trypanosomiasis and more recently cancer.

74 Trypanosoma brucei causes human African trypanosomiasis and regularly switches its major surface

75 Trypanosoma brucei causes human African trypanosomiasis and regularly switches its major surface

76 Trypanosoma brucei causes human African trypanosomiasis and regularly switches its major surface

77 ithin the GlaxoSmithKline HAT (Human African Trypanosomiasis) and Chagas chemical boxes, two collecti

78 ABQ) library against the causative agents of trypanosomiasis, and cutaneous leishmaniasis, identifyin

79 causative agents of malaria, toxoplasmosis, trypanosomiasis, and leishmaniasis, contain a minimal ER

80 ucei, the protozoan parasite causing African trypanosomiasis, and the tsetse (Glossina) vector remain

81 Influenza, plague, and trypanosomiasis are classic examples of zoonotic infecti

82 All four main drugs used for human African trypanosomiasis are toxic, and melarsoprol, the only dru

83 ypanosoma brucei, which causes human African trypanosomiasis, as well as the livestock disease, nagan

84 nt option for reducing the impact of African trypanosomiasis but, although many effective methods hav

85 as new therapeutic targets for human African trypanosomiasis by both genetic and pharmacological mean

86 anti-inflammatory therapies in Human African trypanosomiasis by modulating the NK1 receptor as well a

87 lected parasitic diseases, including African trypanosomiasis caused by the protozoan, Trypanosoma bru

88 n, particularly in the case of Human African Trypanosomiasis caused by Trypanosoma brucei gambiense.

89 mes in two types: East African human African trypanosomiasis caused by Trypanosoma brucei rhodesiense

90 Novel methods for treatment of African trypanosomiasis, caused by infection with Trypanosoma br

91 Human African trypanosomiasis, caused by the eukaryotic parasite Trypa

92 African sleeping sickness or human African trypanosomiasis, caused by Trypanosoma brucei spp., is r

93 soma cruzi , the etiologic agent of American trypanosomiasis (Chagas disease), exhibiting IC(50) valu

94 ishmania spp., which in humans cause African trypanosomiasis, Chagas disease, and leishmaniasis, resp

95 parum, the causative agents of human African trypanosomiasis, Chagas disease, leishmaniasis, and mala

96 ping world, including malaria, human African trypanosomiasis, Chagas disease, leishmaniasis, filarias

97 For selected causes (African trypanosomiasis, congenital syphilis, whooping cough, me

98 osoma brucei, the causative agent of African trypanosomiasis, contains a soluble, vacuolar pyrophosph

99 ber of reported cases, patients with African trypanosomiasis continue to present major challenges to

100 vivo efficacies in the acute mouse model of trypanosomiasis, curing 3/4 or 4/4 animals at 4 x 5 mg/k

101 Treatment of human African trypanosomiasis currently relies on a limited number of

102 also contribute to generating novel African trypanosomiasis disease control strategies.

103 ges resulting from an ongoing suppression of trypanosomiasis disease in cattle in an agropastoral com

104 oma brucei, the etiological agent of African trypanosomiasis, disease progression can be rapid or slo

105 compounds thus shows significant promise for trypanosomiasis drug discovery.

106 are the target of the Pan African Tsetse and Trypanosomiasis Eradication Campaign (PATTEC).

107 The progression of human African trypanosomiasis from the early hemolymphatic stage to th

108 pipeline for treatment of CNS human African trypanosomiasis, giving rise to cautious optimism.

109 fections such as malaria, leishmaniasis, and trypanosomiasis has been steadily increasing.

110 Conversely, human trypanosomiasis has reached epidemic proportions in some

111 human suffering in the form of human African trypanosomiasis (HAT) and Chagas disease.

112 Epidemics of both forms of human African trypanosomiasis (HAT) are confined to spatially stable f

113 nostic and treatment tools for human African trypanosomiasis (HAT) are limited.

114 Human African trypanosomiasis (HAT) caused by Trypanosoma brucei gambi

115 Human African trypanosomiasis (HAT) is a neglected tropical disease ca

116 Human African trypanosomiasis (HAT) is a parasitic disease affecting s

117 Human African trypanosomiasis (HAT) or sleeping sickness is caused by

118 ucei), the causative agent for human African trypanosomiasis (HAT) or sleeping sickness.

119 Human African trypanosomiasis (HAT), a major health concern in sub-Sah

120 ally validated drug target for human African trypanosomiasis (HAT), also called African sleeping sick

121 cei, the causative parasite of human African trypanosomiasis (HAT), also known as African sleeping si

122 Human African trypanosomiasis (HAT), also known as sleeping sickness,

123 worldwide; four in particular (human African trypanosomiasis (HAT), Chagas disease, cutaneous leishma

124 The resurgence of human African trypanosomiasis (HAT), coupled with an increased inciden

125 protozoan parasites that cause human African trypanosomiasis (HAT), depend on ornithine uptake and me

126 eir protective effects against human African trypanosomiasis (HAT), or African sleeping sickness.

127 Human African trypanosomiasis (HAT), or sleeping sickness, is a major

128 ug target for the treatment of human African trypanosomiasis (HAT), raising interest in understanding

129 nity, the parasites that cause human African Trypanosomiasis (HAT), Trypanosoma brucei rhodesiense an

130 serum proteomic signature for human African trypanosomiasis (HAT), using a combination of surface-en

131 ts a promising drug target for human African trypanosomiasis (HAT), which is caused by the parasitic

132 site Trypanosoma brucei causes Human African trypanosomiasis (HAT), which threatens millions of peopl

133 heir potential toward treating human African trypanosomiasis (HAT).

134 ged remain in use for treating human African trypanosomiasis (HAT).

135 (meningoencephalitic) stage of human African trypanosomiasis (HAT).

136 Trypanosoma brucei causes human African trypanosomiasis (HAT).

137 rucei causes the fatal illness human African trypanosomiasis (HAT).

138 nervous system second stage of human African trypanosomiasis (HAT).

139 as a result of protection from human African trypanosomiasis (HAT).

140 ic target for the treatment of human African trypanosomiasis (HAT).

141 Uganda has both forms of human African trypanosomiasis (HAT): the chronic gambiense disease in

142 historical focus of gambiense Human African Trypanosomiasis (HAT, sleeping sickness), a disease that

143 Trypanosoma brucei sp. causes human African trypanosomiasis (HAT; African sleeping sickness).

144 ve agent of sleeping sickness (Human African Trypanosomiasis, HAT), contains a kinetoplast with the m

145 control of sleeping sickness (human African trypanosomiasis, HAT).

146 protozoan and the causative agent of African trypanosomiasis, imports about a thousand proteins into

147 ine, which is currently being tested against trypanosomiasis in humans, and berenil, which is used in

148 anosomes both in vitro and in vivo and cures trypanosomiasis in mice.

149 cause human sleeping sickness and livestock trypanosomiasis in sub-Saharan Africa.

150 plied to a use case of resistance to African trypanosomiasis in the mouse.

151 be developed for treatment of human African trypanosomiasis in the near future, increasing attention

152 esults implicate both forms of human African trypanosomiasis in the selection and persistence of othe

153 ch is used clinically to treat human African trypanosomiasis, inhibits the first step in polyamine (s

154 Relative resistance to African trypanosomiasis is based on the development of a type I

155 Human African trypanosomiasis is caused by a single-celled protozoan p

156 Human African trypanosomiasis is caused by the eukaryotic microbe Tryp

157 The most threatening trypanosomiasis is Chagas disease, affecting up to 12 mi

158 Untreated trypanosomiasis is fatal and the current treatments are

159 ne control of variation in susceptibility to trypanosomiasis is known to occur in mice, where the C57

160 ecular target for treatment of human African trypanosomiasis is ornithine decarboxylase (ODC), which

161 Host resistance to African trypanosomiasis is partially dependent on an early and s

162 eatment of both human and veterinary African trypanosomiasis is still, to a large extent, dependent o

163 chemotherapy for second stage human African trypanosomiasis is unsatisfactory.

164 nt need for new drug development for African trypanosomiasis is widely recognized.

165 amin, traditionally used in the treatment of trypanosomiasis, is under investigation in the treatment

166 anosoma brucei, a causative agent of African trypanosomiasis, is unknown.

167 e parasite Trypanasoma brucei causes African trypanosomiasis, known as sleeping sickness in humans an

168 and model analysis show that suppression of trypanosomiasis leads to increased cattle and human popu

169 brucei, the causative agent of human African trypanosomiasis, led to the identification of substitute

170 Trypanosomiasis, leishmaniasis, and malaria are major pa

171 arasitic diseases (schistosomiasis, malaria, trypanosomiasis, leishmaniasis, and toxoplasmosis) and p

172 aturation, and Ig class switching in African trypanosomiasis may be partially regulated by unusual me

173 diabetes, cirrhosis, Chagas disease, African trypanosomiasis, melanoma, and others.

174 adenosine analogues as drugs against African trypanosomiasis, N(6)-, 2-amino-N(6)-, and N(2)-substitu

175 American Trypanosomiasis or Chagas disease is a prevalent, neglec

176 lsopp argues that those tasked with managing trypanosomiasis or committed to poverty alleviation in A

177 Human African trypanosomiasis or sleeping sickness is a deadly disease

178 added to the pharmacopeia for human African trypanosomiasis (or sleeping sickness), orally dosed fex

179 American trypanosomiasis, or Chagas disease, caused by the protoz

180 American trypanosomiasis, or Chagas' disease, is the leading caus

181 Human African trypanosomiasis, or sleeping sickness, is caused by infe

182 Human African trypanosomiasis, or sleeping sickness, is caused by the

183 veterinary wasting disease and human African trypanosomiasis, or sleeping sickness.

184 e for the fatal human disease called African trypanosomiasis, or sleeping sickness.

185 ypanosoma cruziare the major agents of human trypanosomiasis; other Trypanosomaspecies can cause huma

186 osoma brucei, the causative agent of African trypanosomiasis, possesses a bona fide member of this fa

187 brucei, the causative agent of human African trypanosomiasis, possesses non-canonical mitochondrial p

188 brucei, the causative agent of human African trypanosomiasis, possesses two fatty acid synthesis path

189 The treatment of Human African trypanosomiasis remains a major unmet health need in sub

190 d Central America, Chagas' disease (American trypanosomiasis) remains one of the most prevalent infec

191 n therapy for the treatment of human African trypanosomiasis, renewing interest in nitroheterocycle t

192 s of both early and late stage human African trypanosomiasis, representing a new lead for the develop

193 hat apoptosis could be playing a role in the trypanosomiasis resistance phenotype.

194 Human African trypanosomiasis (sleeping sickness) affects up to half a

195 It has been argued that the risk for trypanosomiasis (sleeping sickness), carried by tsetse f

196 brucei, the causative agent of Human African Trypanosomiasis (sleeping sickness), yet little is known

197 site Trypanosoma brucei causes human African trypanosomiasis ("sleeping sickness") across sub-Saharan

198 resent front line drugs for treating African trypanosomiasis such as melarsoprol (Arsobal) and pentam

199 he analysis of these conflicting outcomes of trypanosomiasis suppression is used to illustrate the ne

200 hypothesis that these APOL1 variants reduce trypanosomiasis susceptibility, resulting in their posit

201 re specific marker for cure of human African trypanosomiasis than parasite DNA.

202 uch as malaria, dysentery, leishmaniasis and trypanosomiasis that are responsible for millions of dea

203 ally involved in the pathogenesis of African trypanosomiasis, the contributions to this disease of CD

204 brucei, the causative agent of human African trypanosomiasis, the NDR kinase, PK50, is expressed in p

205 ysis in the causative agent of human African trypanosomiasis, Trypanosoma brucei, has already shown t

206 The causative agent of human African trypanosomiasis, Trypanosoma brucei, lacks de novo purin

207 soma brucei, the causative agent for African trypanosomiasis undergoes various stages of cellular dif

208 l, melarsoprol (a drug used for treatment of trypanosomiasis), upon induction of apoptosis in cell li

209 protozoan parasite that causes human African trypanosomiasis, uses antigenic variation as a major vir

210 ained from 61 patients in whom human African trypanosomiasis was cured, SL RNA detection had specific

211 falciparum malaria, melioidosis, and African trypanosomiasis, were reported.

212 Trypanosoma cruzi causes American trypanosomiasis, wherein 30-40% of infected individuals

213 nosoma cruzi causes Chagas disease (American trypanosomiasis), which threatens the lives of millions

214 es with faster progression of T.b. gambiense trypanosomiasis, while G1 associates with asymptomatic c

215 a novel test that can diagnose human African trypanosomiasis with high sensitivity and specificity.